oral GLP-1 — 12 things I got wrong before I got it right
Posting this as a discussion rather than a claim: oral GLP-1 — 12 things I got wrong before I got it right.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Why "oral" is doing two completely different jobs in the sentences people write here.
Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.
The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Corrected a cross-class dose comparison in the title. The body is untouched.
daily dosing, not weekly, so the exposure profile is different
Which programme and which readout are you quoting?
the tolerability profile reads broadly similar to the class
Went looking for independent testing on this and found essentially nothing, which was clarifying.
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.
That is a phase 2 result being quoted as though the programme had reported.
Daily dosing, so what does the exposure profile look like across the day?
Daily dosing, so what does the exposure profile look like across the day?
Adding the standing caveat — unapproved, and research material is not for human use.